Arrow Exploration Corp (TSX-V:AXL, AIM:AXL, OTC:CSTPF) has announced the results of its 2022 year-end reserves evaluation by Boury Global Energy Consultants Ltd which saw proved (1P) reserves increase by 11% to 3.37 million barrels of oil equivalent (boe), driven principally through uplift at Tapir (Rio Cravo), Colombia.
In a statement, Marshall Abbott, CEO of Arrow, commented: "Arrow delivered an increase in volumes and pre-tax values across 1P, 2P and 3P reserves in 2022. We are pleased with the results of the BouryGEC reserves evaluation, which reinforces the significant value of our Colombian and Canadian assets.”
Quadrise PLC (AIM:QED) has reported interim financial results for the six-month period ending 31 December 2022 and gave investors an update on its activities in the first quarter.
Despite a drop in cash reserves from £5.6 million to £2.6 million and an increase in losses after tax from £1.5 million to £1.7 million, the company maintains a focus on key projects across the marine, upstream and industrial sectors.
Galliford Try Holdings PLC (LSE:GFRD) said its building business has been appointed to a £75mln contract to create a new build-to-rent residential building in Brent Cross Town, north London.
The appointment was made by Related Argent and Invesco Real Estate on behalf of a separate US account client, the company said in a statement.
NetScientific PLC (AIM:NSCI) has hailed progress at portfolio company PDS Biotechnology Corporation (NASDAQ:PDSB), which passed some key data and development milestones for its lead oncology drug candidate.
For the drug, currently called PDS0101, developments in the past quarter include completing the first stage of enrolment for the VERSATILE-002 Phase II combination trial with Keytruda in patients with human papillomavirus (HPV) and or head and neck cancer.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) has announced the appointment of James O'Brien as its new chief financial officer effective April 3.
O'Brien, who has extensive experience in the US capital markets, will succeed Toni Hänninen, who is leaving the company to pursue a new career opportunity.
Dr Andrew Catchpole, chief scientific officer of hVIVO PLC, is set to deliver a presentation at the World Vaccine Congress in Washington DC.
His presentation - titled 'Challenge Studies, Can the Results be Expected to Mimic Field Trial Data?' - will take place on 5 April.
88 Energy Ltd (AIM:88E, ASX:88E, OTC:EEENF) told investors it has successfully intersected the first three of its reservoir targets in the Hickory well onshore Alaska, with well data indicating the presence of hydrocarbons.
The company, in a statement, said that the drilling had reached around 8,820 feet and had so far encountered all three of the ‘SMD’ reservoir targets (SMD-A, B and C).
Futura Medical PLC (AIM:FUM, OTC:FAMDF) has confirmed the submission of a comprehensive response to the US Food and Drug Administration (FDA) regarding its innovative topical gel treatment for erectile dysfunction (ED), known as MED3000.
It has now provided all requested information and confirmatory data, allowing the regulatory body to continue its review of MED3000.
Infinity Lithium Corporation Ltd (ASX:INF) has soared after subsidiary Extremadura New Energies was granted a key exploration permit over the San José Lithium Project in Spain, which the company describes as a “major milestone”.
This permitting milestone reinforces government and stakeholder commitment to the project, which focuses on the production of battery-grade lithium and hosts the EU’s second-largest JORC-compliant hard rock lithium deposit.
Altech Batteries Ltd (ASX:ATC) and joint venture partner Fraunhofer have launched the design for the CERENERGY® Sodium Alumina Solid State (SAS) 1.0 MWh GridPack (ABS1000) destined for the renewable energy and grid storage market.
Based on preliminary discussions with potential off-takers and to minimise on-site installation of individual ABS60 60KWh battery packs, a pre-installed solution has been launched.